Addex Therapeutics (ADXN) Profit After Tax (2018 - 2026)

Addex Therapeutics has reported Profit After Tax for 9 years, with the latest figure at -$2.2 million in Q1 2026.

• Quarterly Profit After Tax fell 33.43% year-over-year to -$2.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$9.0 million (down 40.27% YoY) and the FY2025 annual result came in at -$8.3 million, down 202.9% from the prior year.
• Profit After Tax advanced to -$2.2 million in Q1 2026 per ADXN's latest filing, from -$2.4 million in the prior quarter.
• Over five years, Profit After Tax peaked at -$1.4 million in Q4 2024 and troughed at -$21.6 million in Q4 2022.
• A 5-year average of -$4.6 million and a median of -$2.6 million in 2023 frame the typical range for Profit After Tax.
• The sharpest annual moves came in 2022 and 2024: Profit After Tax slumped 115.99% in 2022, then jumped 88.43% in 2024.
• Over 5 years, Profit After Tax stood at -$21.6 million in 2022, then soared by 44.89% to -$11.9 million in 2023, then surged by 88.43% to -$1.4 million in 2024, then plunged by 77.38% to -$2.4 million in 2025, then advanced by 10.47% to -$2.2 million in 2026.
• According to Business Quant data, Profit After Tax over the past three periods registered -$2.2 million, -$2.4 million, and -$2.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.